DK3247791T3 - Universal dræber-t-celle - Google Patents

Universal dræber-t-celle Download PDF

Info

Publication number
DK3247791T3
DK3247791T3 DK16701339.0T DK16701339T DK3247791T3 DK 3247791 T3 DK3247791 T3 DK 3247791T3 DK 16701339 T DK16701339 T DK 16701339T DK 3247791 T3 DK3247791 T3 DK 3247791T3
Authority
DK
Denmark
Prior art keywords
killer
universal
cell
universal killer
Prior art date
Application number
DK16701339.0T
Other languages
English (en)
Inventor
Gustav Gaudernack
Sébastien Wälchli
Else Marit Inderberg
Gunnar Kvalheim
Original Assignee
Univ Oslo Hf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oslo Hf filed Critical Univ Oslo Hf
Application granted granted Critical
Publication of DK3247791T3 publication Critical patent/DK3247791T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46443—Growth factors
    • A61K39/464434—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464457—Telomerase or [telomerase reverse transcriptase [TERT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464491—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
    • A61K2239/28—Expressing multiple CARs, TCRs or antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
DK16701339.0T 2015-01-23 2016-01-22 Universal dræber-t-celle DK3247791T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1501175.2A GB201501175D0 (en) 2015-01-23 2015-01-23 A universal T-cell for personalised medicine
PCT/EP2016/051344 WO2016116601A1 (en) 2015-01-23 2016-01-22 Universal killer t-cell

Publications (1)

Publication Number Publication Date
DK3247791T3 true DK3247791T3 (da) 2022-07-11

Family

ID=52673865

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16701339.0T DK3247791T3 (da) 2015-01-23 2016-01-22 Universal dræber-t-celle

Country Status (17)

Country Link
US (2) US11155786B2 (da)
EP (2) EP4095239A1 (da)
JP (1) JP6899333B2 (da)
KR (1) KR102479118B1 (da)
CN (1) CN107250351A (da)
AU (2) AU2016208475B2 (da)
CA (1) CA2973924A1 (da)
DK (1) DK3247791T3 (da)
EA (1) EA201791381A1 (da)
ES (1) ES2922231T3 (da)
GB (1) GB201501175D0 (da)
IL (1) IL253464B (da)
MX (1) MX2017009459A (da)
PL (1) PL3247791T3 (da)
PT (1) PT3247791T (da)
SG (1) SG11201705693XA (da)
WO (1) WO2016116601A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3298033T5 (pl) 2015-05-18 2023-10-30 TCR2 Therapeutics Inc. Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych
WO2017192440A1 (en) * 2016-05-02 2017-11-09 Cerus Corporation Compositions and methods for improved nk cell therapies
JP7109789B2 (ja) 2016-08-02 2022-08-01 ティーシーアール２ セラピューティクス インク． 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法
IL292551B2 (en) 2016-10-07 2023-10-01 Tcr2 Therapeutics Inc Preparations and methods for reprogramming T-cell receptors using fusion proteins
US11851491B2 (en) 2016-11-22 2023-12-26 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
US20190358263A1 (en) 2016-12-07 2019-11-28 Oslo Universitetssykehus Hf Compositions and Methods for Cell Therapy
US11752172B2 (en) * 2017-01-04 2023-09-12 Nova Southeastern University Natural killer (NK) cells expressing an antigen-specific functional T cell receptor (TCR) complex, methods for production thereof, and methods for therapeutic use thereof
EP3844499A1 (en) * 2018-08-31 2021-07-07 Invectys Sa Method to assess car functionality
JP6977969B2 (ja) * 2019-03-22 2021-12-08 株式会社ガイアバイオメディシン 免疫細胞提供システム
EP3750547A1 (en) 2019-06-13 2020-12-16 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Modified nk-92 cells, and therapeutic and diagnostic uses thereof
CN111662871A (zh) * 2020-06-11 2020-09-15 福建医科大学孟超肝胆医院(福州市传染病医院) 一种核酸适体功能化nk细胞及其制备与应用
WO2022063966A1 (en) 2020-09-24 2022-03-31 Medigene Immunotherapies Gmbh Prame specific t-cell receptors and uses thereof
JP2023547695A (ja) * 2020-11-03 2023-11-13 ハンチョウ キハン バイオテック カンパニー リミテッド 増強された免疫療法のためのシステムおよび方法
GB202017873D0 (en) 2020-11-12 2020-12-30 Olso Unversitetssykehus Hf Method of determining DLBCL prognosis
WO2022250312A1 (ko) * 2021-05-27 2022-12-01 (주)에스엠티바이오 신경내분비종양의 치료용 자연살해세포
WO2023047089A1 (en) 2021-09-21 2023-03-30 Oslo Universitetssykehus Hf Binding proteins for terminal deoxynucleotidyl transferase (tdt)
WO2023078287A1 (en) * 2021-11-03 2023-05-11 Hangzhou Qihan Biotechnology Co., Ltd. Systems and methods for enhanced immunotherapies

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124251A (en) 1990-01-31 1992-06-23 Becton, Dickinson And Company CD3 ζ co-associated complex on CD16- NK cells
WO1998049268A1 (en) 1997-04-30 1998-11-05 Hans Klingemann Natural killer cell lines and methods of use
IL127142A0 (en) 1998-11-19 1999-09-22 Yeda Res & Dev Immune cells having predefined biological specificity
EP1470159B1 (en) 2001-12-04 2013-08-07 Dana-Farber Cancer Institute, Inc. Antibody to latent membrane proteins and uses thereof
PT2921500T (pt) * 2004-07-10 2023-09-25 The Institute For Cancer Res Linhas de células assassinas naturais humanas modificadas geneticamente
WO2006050270A2 (en) * 2004-11-02 2006-05-11 The Government Of The United States Of America As Represented By The Secretary Department Of Health & Human Services Compositions and methods for treating hyperproliferative disorders
US8518697B2 (en) 2006-04-04 2013-08-27 Washington University Single chain trimers and uses therefor
CN101631138A (zh) 2008-07-18 2010-01-20 深圳富泰宏精密工业有限公司 个人信息代理系统及方法
WO2010088160A1 (en) * 2009-01-28 2010-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors and related materials and methods of use
DK2817620T3 (da) * 2012-02-22 2016-09-05 Verik Bio Inc System til immunterapi rettet mod tumorformering og -progression
EP2893003B1 (en) 2012-09-04 2021-03-31 Inven2 AS Selective and controlled expansion of educated nk cells
EP2948544A4 (en) 2013-01-28 2016-08-03 St Jude Childrens Res Hospital CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES
US20150361150A1 (en) 2013-02-04 2015-12-17 Roger Williams Medical Center Methods and compositions for treating gastrointestinal stromal tumor (gist)
JP6425301B2 (ja) 2014-05-29 2018-11-21 国立大学法人富山大学 Ｔｃｒの細胞傷害活性誘導能を評価するためのｎｋ細胞株、およびその作製方法
US10550197B2 (en) 2014-06-18 2020-02-04 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus CAR-expressing NK-92 cells as cell therapeutic agents
US20170274014A1 (en) * 2014-07-21 2017-09-28 Jennifer Brogdon Combinations of low, immune enhancing, doses of mtor inhibitors and cars

Also Published As

Publication number Publication date
NZ733855A (en) 2023-10-27
EP3247791B1 (en) 2022-05-04
AU2022200126A1 (en) 2022-02-10
IL253464A0 (en) 2017-09-28
PT3247791T (pt) 2022-07-20
AU2016208475B2 (en) 2021-10-14
US20180010097A1 (en) 2018-01-11
WO2016116601A1 (en) 2016-07-28
EA201791381A1 (ru) 2018-02-28
US20220127574A1 (en) 2022-04-28
KR102479118B1 (ko) 2022-12-16
BR112017015631A2 (pt) 2018-03-13
SG11201705693XA (en) 2017-08-30
EP3247791A1 (en) 2017-11-29
US11155786B2 (en) 2021-10-26
ES2922231T3 (es) 2022-09-12
AU2016208475A1 (en) 2017-08-03
JP2018512047A (ja) 2018-05-10
GB201501175D0 (en) 2015-03-11
MX2017009459A (es) 2018-04-11
CA2973924A1 (en) 2016-07-28
KR20170121178A (ko) 2017-11-01
PL3247791T3 (pl) 2022-09-05
IL253464B (en) 2022-04-01
JP6899333B2 (ja) 2021-07-07
CN107250351A (zh) 2017-10-13
EP4095239A1 (en) 2022-11-30

Similar Documents

Publication Publication Date Title
DK3247791T3 (da) Universal dræber-t-celle
DK3283625T3 (da) Nukleasemedieret genomeditering
DK3218519T3 (da) Multipass-sekvensering
DK3331869T3 (da) Muscarinagonister
DK3305788T3 (da) Janus-kinase-hæmmer
DK4032440T3 (da) Låganordning
DK3277719T3 (da) Polypeptider
DK3331528T3 (da) Muskarinagonister
DK3360890T3 (da) Genterapi
DK3310450T3 (da) Olie-vand-separator
DK3331529T3 (da) Muskarinagonister
DK3341303T3 (da) Blisterpakning
DK3270930T3 (da) Præeklampsi
DK3292136T3 (da) Penicillin-g-acylaser
DK3394281T3 (da) Gærcelle
DK3766582T3 (da) Cellekultur
DE112015006486A5 (de) Inkubationsrinne
DK3318308T3 (da) Badmintonketsjer
DK3274482T3 (da) Stenborsknop
DE112016005599A5 (de) Strahlungsgrill
DE112015005904A5 (de) Gurtschlossbringer
ES1140083Y (es) Descompatactador tetrafunción
DE102015206660A8 (de) Plattenaufteilanlage
DK3390621T3 (da) Forbedret fermentering
DE112016001124A5 (de) Spannschutz